Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes
- PMID: 34863701
- PMCID: PMC9432310
- DOI: 10.1016/j.jped.2021.08.006
Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes
Abstract
Objective: The clinical cases of patients with multisystem inflammatory syndrome (MIS-C) were analyzed via a systematic review and meta-analysis of the clinical findings, treatments, and possible outcomes of articles retrieved via database searches.
Sources: The authors searched the PubMed, Scielo, Web of Science, Science Direct, EMBASA, EBSCO, and Scopus databases for articles containing the keywords "multisystem inflammatory syndrome in children" or "MIS-C" or "PIMS-TS" or "SIMP" and "COVID-19" or "SARS-CoV-2" published between December 1st, 2019 and July 10th, 2021. Patient characteristics, tissue and organ comorbidities, the incidence of symptoms after COVID-19 infection, treatment, and patient evolution in the articles found were evaluated. The data were abstracted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and Newcastle-Ottawa Scale (NOS).
Findings: In total, 98 articles (2275 patients) were selected for demographics, clinical treatment, and outcomes of patients diagnosed with MIS-C. The average age of children with MIS-C, 56.8% of whom were male, was of nine years. Fever (100%), gastrointestinal (GI) (82%), and abdominal pain (68%) were the decisive symptoms for the diagnosis of MIS-C. Shock and/or hypotension were common in patients with MIS-C. Cardiac symptoms (66%) predominated over respiratory (39%) and neurological (28%) symptoms. MIS-C treatment followed the common guidelines for treating children with septic shock and Kawasaki disease (KD) and proved to be effective.
Conclusions: This meta-analysis highlights the main clinical symptoms used for the diagnosis of MIS-C, the differences between MIS-C and KD, and the severity of the inflammatory process and urgency for hospital care.
Keywords: COVID-19; Children; MIS-C; PIMS-TS; SARS-CoV-2.
Copyright © 2021 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.
Conflict of interest statement
Conflicts of interest The authors declare no conflicts of interest.
Figures
Similar articles
-
Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review.J Pediatr Rehabil Med. 2020;13(3):301-316. doi: 10.3233/PRM-200794. J Pediatr Rehabil Med. 2020. PMID: 33252101 Review.
-
Publishing in pandemic times: A bibliometric analysis of early medical publications on Kawasaki-like disease (MIS-C, PIMS-TS) related to SARS-CoV-2.Arch Pediatr. 2021 Aug;28(6):464-469. doi: 10.1016/j.arcped.2021.05.002. Epub 2021 May 28. Arch Pediatr. 2021. PMID: 34140220
-
Multisystem inflammatory syndrome in children related to COVID-19: a systematic review.Eur J Pediatr. 2021 Jul;180(7):2019-2034. doi: 10.1007/s00431-021-03993-5. Epub 2021 Feb 18. Eur J Pediatr. 2021. PMID: 33599835 Free PMC article. Review.
-
Similarities and differences between multiple inflammatory syndrome in children associated with COVID-19 and Kawasaki disease: clinical presentations, diagnosis, and treatment.World J Pediatr. 2021 Aug;17(4):335-340. doi: 10.1007/s12519-021-00435-y. Epub 2021 May 20. World J Pediatr. 2021. PMID: 34013488 Free PMC article. Review.
-
Multisystem Inflammatory Syndrome in Children (MIS-C).Curr Allergy Asthma Rep. 2022 May;22(5):53-60. doi: 10.1007/s11882-022-01031-4. Epub 2022 Mar 22. Curr Allergy Asthma Rep. 2022. PMID: 35314921 Free PMC article. Review.
Cited by
-
SARS-CoV-2 parental vaccination and risk of multisystem inflammatory syndrome in children: a single-center retrospective study.Clin Exp Vaccine Res. 2024 Jul;13(3):225-231. doi: 10.7774/cevr.2024.13.3.225. Epub 2024 Jul 31. Clin Exp Vaccine Res. 2024. PMID: 39144126 Free PMC article.
-
Therapeutic implications of quercetin and its derived-products in COVID-19 protection and prophylactic.Heliyon. 2024 Apr 30;10(9):e30080. doi: 10.1016/j.heliyon.2024.e30080. eCollection 2024 May 15. Heliyon. 2024. PMID: 38765079 Free PMC article. Review.
-
Vitamin D Supplementation in Neonatal and Infant MIS-C Following COVID-19 Infection.Int J Mol Sci. 2024 Mar 27;25(7):3712. doi: 10.3390/ijms25073712. Int J Mol Sci. 2024. PMID: 38612523 Free PMC article. Review.
-
Severe pediatric COVID-19: a review from the clinical and immunopathophysiological perspectives.World J Pediatr. 2024 Apr;20(4):307-324. doi: 10.1007/s12519-023-00790-y. Epub 2024 Feb 6. World J Pediatr. 2024. PMID: 38321331 Free PMC article. Review.
-
"Multisystem Inflammatory Syndrome in Children"-Like Disease after COVID-19 Vaccination (MIS-V) with Potential Significance of Functional Active Autoantibodies Targeting G-Protein-Coupled Receptors (GPCR-fAAb) for Pathophysiology and Therapy.Children (Basel). 2023 Nov 22;10(12):1836. doi: 10.3390/children10121836. Children (Basel). 2023. PMID: 38136038 Free PMC article.
References
-
- RCPCH. Paediatric multisystem inflammatory syndrome temporally associated with COVID- 19 (PIMS) - guidance for clinicians. 2020;178:379-85. [Cited 2020 Nov 23]. Available from:https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-sy....
-
- CDC . 2020. Centers for disease control and prevention. Emergency Preparedness and Response: Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. May 14.
-
- WHO . WHO; Geneva: 2020. Organization World Health. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous